UNSPSC 51182026: Ethylestrenol

This classification denotes an anabolic steroid with the molecular formula C20H32O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ADC79EK5Q8, chemically known as 19-norpregn-4-en-17-ol, (17.alpha.)- but generally known as ethylestrenol, which bears US NIH Compound Identifier 3302. European Medicines Agency schedules Ethylestrenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07291MIG.

UNSPSC 51182026 Ethylestrenol, a Commodity code, encompasses pharmaceutical products supplied through state and local cooperative purchasing agreements. State and local governments acquire ethylestrenol and related pharmaceutical inventory through multistate cooperative contracting vehicles that establish standing agreements with manufacturers for distribution via authorized wholesalers to government health facilities, hospitals, clinics, and related medical institutions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a primary issuing body under this code. Solicitations typically target manufacturers capable of certifying compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintaining relationships with authorized pharmaceutical wholesalers, and managing chargeback systems and electronic data interchange (EDI) infrastructure. Evaluation emphasizes price competitiveness, administrative compliance, and flexibility in pricing models including flat price, net price formats, and WAC-minus structures.

MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products, with responses due March 26, 2026, illustrates current procurement activity under the code. The solicitation covers Minnesota and participating states including Oregon and establishes two-year agreements effective July 1, 2026, with optional extensions. Vendors must carry insurance including $5 million commercial general liability per occurrence and $2 million in network security and privacy liability. Performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. Products must be available in the marketplace by May 15, 2026, possess FDA approval, and maintain a minimum six-month shelf life. The RFP does not disclose specific award values or budget ranges, though vendors pay a 3 percent administrative fee on contract purchases. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.